Daré Bioscience’s (DARE) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Daré Bioscience (NASDAQ:DARE) in a report issued on Friday morning,Benzinga reports. They currently have a $12.00 target price on the biotechnology company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Daré Bioscience in a report on Wednesday, August 14th.

Daré Bioscience Stock Performance

Shares of DARE stock opened at $3.20 on Friday. The firm has a fifty day moving average of $3.56 and a 200-day moving average of $3.93. Daré Bioscience has a 52-week low of $3.05 and a 52-week high of $7.56. The stock has a market cap of $27.35 million, a price-to-earnings ratio of -5.44 and a beta of 1.34.

Hedge Funds Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC lifted its holdings in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 778,700 shares of the biotechnology company’s stock after acquiring an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is owned by hedge funds and other institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.